News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The consideration for the acquisition is US $ 2.25 million
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
It is the world’s first DNA-based Covid vaccine
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
Expertise in exosomes isolation and characterization will drive innovation in this field
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Subscribe To Our Newsletter & Stay Updated
